Accurate Education - Nicotinamide Riboside (NAD+ Precursors) for Chronic Pain: A Patient Guide

Nutraceuticals:

Nicotinamide Riboside (NAD+ Precursors) for Chronic Pain: A Patient Guide

Nicotinamide Riboside (NR), a Vitamin B3 derivative and NAD+ precursor, shows promise for managing chronic pain by boosting cellular NAD+ levels, which reduces inflammation and supports mitochondrial function. Studies indicate NR can alleviate neuropathic and inflammatory pain in animal models, specifically reducing chemotherapy-induced peripheral neuropathy.

See:

Nutraceutical Patient Guides:

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

Nicotinamide Riboside (NAD+ Precursors) for Chronic Pain: A Patient Guide

1. OVERVIEW

Nicotinamide riboside (NR) is a form of vitamin B3 and a precursor to nicotinamide adenine dinucleotide (NAD+), an essential coenzyme present in all living cells. NAD+ plays critical roles in energy metabolism, DNA repair, cellular signaling, and mitochondrial function.[1][2] NAD+ levels decline with aging and in chronic disease states, contributing to cellular dysfunction.[3]

What makes NAD+ precursors valuable for chronic pain:

Restores mitochondrial function in damaged sensory neurons[4][5][6]
Activates SIRT1, a key enzyme that suppresses pain genes and inflammation[4][7][8]
Reduces oxidative stress and protects neurons from damage[2][9]
Supports nerve regeneration and repair[5][6]
Addresses the underlying cellular energy deficits that contribute to chronic pain[10][9]

How NAD+ Precursors Compare to Conventional Medications:

Unlike traditional pain medications that primarily mask symptoms, NAD+ precursors target fundamental cellular processes underlying chronic pain—particularly mitochondrial dysfunction and neuroinflammation.[4][9] Preclinical studies in animal models of neuropathic pain show that NR supplementation can prevent and reverse tactile hypersensitivity and pain-related behaviors.[4][10][5][6] A landmark study found that NR prevented the development of chemotherapy-induced peripheral neuropathy and reversed established neuropathy in a subset of animals, with effects sustained even after a 2-week washout period.[10]

However, it is important to note that while preclinical evidence is strong, human clinical trials specifically for pain conditions are still limited.[1][11] The efficacy observed in animal studies has not yet been fully replicated in human trials for pain.[1] NAD+ precursors have an excellent safety profile and do not cause dependence, tolerance, or significant side effects.[12][13][14][11]

—

2. DIETARY SOURCES

NAD+ can be synthesized from several dietary precursors:

Nicotinamide Riboside (NR):

Cow milk: Contains approximately 12 μmol NAD+ precursors per liter, with 40% as NR[15]
Conventional milk contains more NR than organic milk[15]
Small amounts in yeast-containing foods

Nicotinamide Mononucleotide (NMN):

Edamame, broccoli, cucumber, cabbage, avocado[16]
Tomatoes, mushrooms
Raw beef and shrimp

Other NAD+ Precursors (Nicotinamide and Nicotinic Acid):

Meat (especially liver), fish, poultry
Nuts and legumes
Whole grains and fortified cereals
Mushrooms

Important Bioavailability Note: Dietary sources provide only trace amounts of NR and NMN compared to therapeutic doses. Oral NR supplements are well-absorbed and dose-dependently increase blood NAD+ levels (22% increase at 100 mg, 51% at 300 mg, and 142% at 1000 mg).[12]

Recent research shows that orally administered NR and NMN undergo significant gut microbiota-mediated conversion to nicotinic acid before being used for NAD+ synthesis in the liver.[17] This enterohepatic circulation pathway is an important consideration for understanding how these supplements work.

—

3. INDICATIONS FOR NUTRACEUTICAL SUPPLEMENTATION

Pain Conditions with Preclinical Evidence (Animal Studies):

Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Strong Preclinical Evidence

NR prevented and reversed paclitaxel-induced tactile hypersensitivity and pain-aversive behaviors in rats[10]
Effects were sustained after a 2-week washout period[10]
NR did not interfere with the anti-cancer effects of chemotherapy[10]

Diabetic Peripheral Neuropathy – Strong Preclinical Evidence

NR and NMN reversed sensory dysfunction, normalized nerve conduction velocities, and restored intraepidermal nerve fibers in diabetic mice[5][6]
Benefits occurred through SIRT1 activation and mitochondrial repair[5][7]

Trigeminal Neuropathic Pain – Strong Preclinical Evidence

NR supplementation significantly ameliorated trigeminal neuropathic pain in mice[4]
Multi-omics studies showed NR suppresses key pain genes and exerts anti-inflammatory effects[4]

Conditions with Theoretical Benefit (Based on Mechanism):

Fibromyalgia (mitochondrial dysfunction is implicated)[18]
Small fiber neuropathy
Age-related chronic pain conditions
Inflammatory pain conditions

Note: Human clinical trials specifically for pain conditions are limited. Most human evidence comes from safety and metabolic studies rather than pain-specific outcomes.[1][11]

—

4. NAD+ PRECURSORS’ IMPACT ON PAIN CONDITIONS

NAD+ precursors address the underlying pathophysiology of chronic pain through multiple mechanisms:

Mitochondrial Restoration:

Chronic pain conditions are associated with severe mitochondrial impairment in sensory neurons[4]
NR supplementation enhances mitochondrial fitness, restoring energy production capacity[4][6]
Improves mitochondrial membrane potential and ATP synthesis[6]
Promotes mitochondrial biogenesis through SIRT1/PGC-1α pathway activation[4][8]

Nerve Protection and Regeneration:

Protects dorsal root ganglion (DRG) neurons from damage[5][6]
Promotes neurite growth in cultured neurons[5]
Restores intraepidermal nerve fiber density in diabetic neuropathy models[5][6]
Normalizes nerve conduction velocities[5][6]

Anti-Inflammatory Actions:

SIRT1 activation suppresses NF-κB, the master regulator of inflammation[19][20][21]
Reduces pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)[19][21]
Decreases COX-2 and iNOS expression[19]
Suppresses a broad range of key pain genes in sensory ganglia[4]

—

5. NAD+ PRECURSORS’ IMPACT ON PAIN PROCESSING

Pain processing refers to how pain signals are processed from the initial damaged tissue source of pain through the nerves and spinal cord to the brain and then down the spinal cord again. NAD+ precursors offer potential benefit for reducing the severity of the pain experience by acting at various levels of pain processing.

Level 1: Peripheral Pain Receptor (Nociception Transduction)

Protects peripheral nerve endings from oxidative damage[2][9]
Reduces local inflammatory mediators that sensitize nociceptors[4][19]
Supports energy metabolism in sensory nerve terminals[9]

Level 2: Primary Afferent Transmission to Spinal Cord

Restores mitochondrial function in dorsal root ganglion neurons[4][5][6]
Protects axons from degeneration through SIRT1-mediated mechanisms[4][8]
Maintains nerve conduction velocity[5][6]

Level 3: Spinal Cord Dorsal Horn Processing (First Synapse)

SIRT1 activation regulates synaptic plasticity of spinal dorsal horn neurons[7]
Reduces enhanced structural synaptic plasticity associated with central sensitization[7]
Decreases levels of synapse-associated proteins (PSD-95, GAP43, synaptophysin)[7]

Level 4: Ascending Spinal Pathways and Supraspinal Processing

Provides neuroprotection in ascending pain pathways[3][2]
Reduces neuroinflammation in supraspinal structures[2]

Level 5: Brain Cortical Processing and Pain Perception

NAD+ precursors have demonstrated neuroprotective effects in brain tissue[3][2]
May improve cognitive function affected by chronic pain[22][3]

Level 6: Descending Pain Modulation

SIRT1 activation may enhance descending inhibitory pathways[8][23]
Reduces central inflammatory processes that impair descending modulation[19][20]

—

6. BENEFITS FOR PAIN SENSITIZATION

Peripheral Sensitization: MODERATE Quality Evidence (Preclinical)

Protects peripheral sensory neurons from damage and dysfunction[4][10][5][6]
Reduces inflammatory mediators at the site of nerve injury[4][19]
Restores normal sensory thresholds in animal models of neuropathy[10][5][6]
Prevents development of tactile hypersensitivity when given prophylactically[10]

Central Sensitization: MODERATE Quality Evidence (Preclinical)

SIRT1 activation inhibits enhanced synaptic plasticity in spinal dorsal horn[7]
Reduces spinal cord neuroinflammation through NF-κB suppression[19][20][21]
Decreases synapse-associated proteins involved in central sensitization[7]
Reverses established pain behaviors in some animal models[10][5]

—

7. NAD+ PRECURSORS’ IMPACT ON THE 4 DRIVING FORCES OF CHRONIC PAIN

1. Systemic Inflammation: MODERATE EFFECT

SIRT1 activation suppresses NF-κB, reducing production of inflammatory cytokines[19][20][21]
Decreases TNF-α, IL-1β, and IL-6 through epigenetic mechanisms[19][21]
Inhibits COX-2 and iNOS expression[19]
Human studies show NAD+ precursors are safe but anti-inflammatory effects in humans need more research[11]

2. Neuroinflammation: STRONG EFFECT (Preclinical)

Multi-omics studies demonstrate NR exerts broad anti-inflammatory effects in sensory ganglia[4]
SIRT1 activation suppresses microglial and astrocyte activation[8][23]
Reduces neuroinflammatory gene expression in injured nerves[4]
Protects neurons from inflammatory damage[2][9]

3. Oxidative Stress: STRONG EFFECT

NAD+ is essential for cellular redox balance and antioxidant defense[2][9]
Supports glutathione recycling and other antioxidant systems[2]
Protects against reactive oxygen species (ROS) damage[2][24]
Reduces oxidative damage markers in preclinical studies[23]
NAD+ depletion from excessive PARP activation (DNA repair enzyme) during oxidative stress is prevented by supplementation[2][9]

4. Mitochondrial Dysfunction: VERY STRONG EFFECT (Primary Mechanism)

This is the primary mechanism by which NAD+ precursors may benefit chronic pain:

NAD+ is essential for mitochondrial electron transport chain function[2][9]
Restores mitochondrial maximum reserve capacity in damaged neurons[6]
Promotes mitochondrial biogenesis through SIRT1/PGC-1α pathway[4][8]
– Improves ATP production in energy-depleted cells[2][9]
Protects against mitochondrial dysfunction-induced axon degeneration[4][6][9]

—

8. DOSING, TIMING, DURATION AND ADMINISTRATION

Recommended Dosing (Based on Human Safety Studies):

General supplementation

Dose: 250-500 mg/day
Timing: With or without food
Duration: Ongoing

Neuropathic pain (theoretical)

Dose: 500-1000 mg/day
Timing: Divided doses (morning and evening)
Duration: Minimum 8-12 weeks

Chemotherapy neuropathy prevention

Dose: 500-1000 mg/day
Timing: Start before chemotherapy
Duration: Throughout treatment

Age-related conditions

Dose: 300-1000 mg/day
Timing: Morning preferred
Duration: Ongoing

Key Dosing Points:

Human studies have used doses ranging from 100 mg to 3000 mg daily with good tolerability[12][13][14]
1000 mg twice daily (2000 mg/day) was safe in a 12-week trial[13]
1500 mg twice daily (3000 mg/day) was safe in a 4-week trial in Parkinson’s patients[14]
Dose-dependent increases in blood NAD+ levels: 100 mg (22%), 300 mg (51%), 1000 mg (142%)[12]
EFSA (European Food Safety Authority) considers up to 300 mg/day safe for general adult population; up to 230 mg/day for pregnant/lactating women[25]

Timing:

Can be taken with or without food
Morning dosing may be preferred to align with circadian NAD+ metabolism
If taking divided doses, morning and early evening are reasonable

Duration of Onset:

Blood NAD+ levels increase within 2 weeks of supplementation[12]
Pain benefits in animal studies were observed after 2-4 weeks of treatment[10][5]
Allow minimum 8-12 weeks to assess clinical benefit for pain conditions

NMN Dosing (Alternative NAD+ Precursor):

Human studies have used 250-1250 mg/day[11]
Similar safety profile to
May be converted to NR before cellular uptake[26][17]

—

9. FORMULATION CONSIDERATIONS

Nicotinamide Riboside (NR):

Most studied NAD+ precursor for human use[11]
Available as nicotinamide riboside chloride (NIAGEN®)[12]
Generally Recognized as Safe (GRAS) status in the US[12]
Novel Food approval in EU at doses up to 300 mg/day[25]
NR is a reactive molecule with stability challenges during manufacturing and storage[27]
NR borate formulations may offer improved stability[27]

Nicotinamide Mononucleotide (NMN):

Another well-studied NAD+ precursor[11][28]
May require conversion to NR before cellular uptake[26]
Recent research suggests both NR and NMN undergo gut microbiota-mediated conversion to nicotinic acid[17]
Similar efficacy to NR in preclinical studies[5][6]

Quality Considerations:

Choose products from reputable manufacturers with third-party testing
Look for USP Verified or NSF Certified products
Store in cool, dry conditions to maintain stability
NR is sensitive to heat and moisture[27]

Combination Products:

NR + pterostilbene combinations have been studied (Basis®)[11]
Pterostilbene is a SIRT1 activator that may enhance NR effects[11]

—

10. SYNERGIES WITH OTHER PAIN MEDICATIONS AND NUTRACEUTICALS

Nutraceuticals with Potential Synergy:

Resveratrol/Pterostilbene: SIRT1 activators that may enhance NAD+ precursor effects[11][8]
Metformin: Both activate AMPK pathway; potential synergy for metabolic conditions[22]
Chemotherapy agents: NR did not interfere with myelosuppressive effects of paclitaxel in animal studies[10]

—

11. DRUG INTERACTIONS

Generally Safe – No Known Significant Interactions:

NSAIDs
Acetaminophen
Gabapentinoids
Most antidepressants
Opioids

Theoretical Considerations (Monitor):

Chemotherapy agents: While animal studies suggest NR does not interfere with chemotherapy efficacy, discuss with oncologist before use[10]
Immunosuppressants: NAD+ metabolism affects immune function; theoretical concern[30]
Diabetes medications: NAD+ precursors may affect glucose metabolism; monitor blood sugar[13][16]

Potential Concerns:

High-dose niacin (nicotinic acid): Avoid combining high doses of multiple NAD+ precursors to prevent excessive NAD+ metabolite accumulation[30]
PARP inhibitors (cancer drugs): Theoretical interaction as both affect NAD+ metabolism[9][30]

Note: NAD+ precursors have been studied in numerous clinical trials with excellent safety profiles and no significant drug interactions reported.[12][13][14][11] However, long-term interaction studies are limited.

—

12. SAFETY AND CONTRAINDICATIONS

Generally Favorable Safety Profile:

Multiple clinical trials confirm NR and NMN are well-tolerated with few adverse effects.[12][13][14][11]

Common Side Effects (Generally Mild):

Mild gastrointestinal discomfort (nausea, bloating)
Flushing (rare with NR, unlike nicotinic acid)[12]
Headache (uncommon)
Fatigue (uncommon)

Important: Unlike nicotinic acid (niacin), NR does not cause flushing.[12]

Safety Data from Clinical Trials:

8-week trial (100-1000 mg/day): No significant adverse events vs. placebo[12]
12-week trial (2000 mg/day): No serious adverse events; safety blood tests normal[13]
– 4-week trial (3000 mg/day): Well-tolerated in Parkinson’s patients[14]

Contraindications:

Known allergy to nicotinamide riboside or related compounds
Pregnancy and lactation (insufficient safety data; EFSA recommends ≤230 mg/day)[25]

Use with Caution:

Active cancer (theoretical concern about NAD+ supporting tumor metabolism)[30]
Severe liver disease (NAD+ metabolism occurs primarily in liver)
Severe kidney disease (limited data)

Theoretical Long-Term Concerns (Require More Research):[30]

Potential accumulation of NAD+ metabolites
Theoretical concerns about cellular senescence promotion
Possible effects on tumor biology (both protective and potentially promoting)

—

13. SPECIAL CONSIDERATIONS / TIPS

Start with lower doses: Begin with 250-300 mg/day and increase gradually over 1-2 weeks
Be patient: Allow 8-12 weeks to assess benefit for pain conditions
Quality matters: Choose reputable brands with third-party testing; NR is sensitive to degradation
Storage: Keep in cool, dry place; some products require refrigeration
Timing: Morning dosing may align better with natural circadian NAD+ rhythms
Combination approach: Consider combining with other mitochondrial support (CoQ10, B-vitamins)
For chemotherapy patients: Discuss with oncologist; animal data suggests NR may prevent CIPN without affecting chemotherapy efficacy[10]
Monitor blood sugar: If diabetic, NAD+ precursors may affect glucose metabolism[13]
Realistic expectations: Strong preclinical evidence, but human pain trials are limited; benefits may be modest
NR vs. NMN: Both appear effective; NR has more human safety data; recent research suggests similar metabolic fates[17]
Gut health matters: Gut microbiota play a role in NAD+ precursor metabolism[17]

—

14. COSTS

Nicotinamide Riboside (NR): $30-60 per month (250-500 mg/day); $60-120 per month (1000 mg/day)
Nicotinamide Mononucleotide (NMN): $40-80 per month (250-500 mg/day); $80-150 per month (1000 mg/day)
Combination products (NR + pterostilbene): $40-70 per month

NAD+ precursors are among the more expensive supplements. They are sold as dietary supplements in the United States and do not require a prescription. Prices vary significantly by brand and formulation. NMN tends to be more expensive than NR.

—

Remember: NAD+ precursors represent a promising approach to chronic pain that targets fundamental cellular processes—particularly mitochondrial dysfunction and neuroinflammation. While preclinical evidence is strong, especially for neuropathic pain conditions, human clinical trials specifically for pain are still needed.

The excellent safety profile makes NAD+ precursors a reasonable option to consider, particularly for patients with neuropathic pain, chemotherapy-induced neuropathy, or conditions associated with mitochondrial dysfunction.

Always discuss any new supplement with your healthcare provider before starting, especially if you have cancer, diabetes, or are taking other medications.

The evidence base differs from melatonin in that NAD+ precursors have very strong preclinical (animal) data for neuropathic pain conditions—particularly chemotherapy-induced and diabetic peripheral neuropathy—but human clinical trials specifically examining pain outcomes remain limited.[1][10][5][6][11]

The primary mechanism involves restoration of mitochondrial function and SIRT1 activation, which suppresses pain genes and neuroinflammation.[4][8] Safety data from multiple human trials supports doses up to 3000 mg/day for short-term use.[12][13][14]

References

NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects. Yaku K, Nakagawa T. Antioxidants & Redox Signaling. 2023;39(16-18):1133-1149. doi:10.1089/ars.2023.0354.
Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes. Braidy N, Berg J, Clement J, et al. Antioxidants & Redox Signaling. 2019;30(2):251-294. doi:10.1089/ars.2017.7269.
Preclinical and Clinical Evidence of NAD Precursors in Health, Disease, and Ageing. Reiten OK, Wilvang MA, Mitchell SJ, Hu Z, Fang EF. Mechanisms of Ageing and Development. 2021;199:111567. doi:10.1016/j.mad.2021.111567.
Restoration of Mitochondrial Function Alleviates Trigeminal Neuropathic Pain in Mice. Yang J, Xie S, Guo J, et al. Free Radical Biology & Medicine. 2025;226:185-198. doi:10.1016/j.freeradbiomed.2024.11.011.
NAD+ Precursors Reverse Experimental Diabetic Neuropathy in Mice. Chandrasekaran K, Najimi N, Sagi AR, et al. International Journal of Molecular Sciences. 2024;25(2):1102. doi:10.3390/ijms25021102.
NAD+ Precursors Repair Mitochondrial Function in Diabetes and Prevent Experimental Diabetic Neuropathy. Chandrasekaran K, Najimi N, Sagi AR, et al. International Journal of Molecular Sciences. 2022;23(9):4887. doi:10.3390/ijms23094887.
Sirtuin 1 Alleviates Diabetic Neuropathic Pain by Regulating Synaptic Plasticity of Spinal Dorsal Horn Neurons. Zhang Z, Ding X, Zhou Z, et al. Pain. 2019;160(5):1082-1092. doi:10.1097/j.pain.0000000000001489.
SIRT1: A Promising Therapeutic Target for Chronic Pain. Song FH, Liu DQ, Zhou YQ, Mei W. CNS Neuroscience & Therapeutics. 2022;28(6):818-828. doi:10.1111/cns.13838.
NAD Metabolism in Peripheral Neuropathic Pain. Dai Y, Lin J, Ren J, et al. Neurochemistry International. 2022;161:105435. doi:10.1016/j.neuint.2022.105435.
Nicotinamide Riboside, a Form of Vitamin B3 and NAD+ Precursor, Relieves the Nociceptive and Aversive Dimensions of Paclitaxel-Induced Peripheral Neuropathy in Female Rats. Hamity MV, White SR, Walder RY, et al. Pain. 2017;158(5):962-972. doi:10.1097/j.pain.0000000000000862.
Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023;78(12):2435-2448. doi:10.1093/gerona/glad106.
Safety and Metabolism of Long-Term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Healthy Overweight Adults. Conze D, Brenner C, Kruger CL. Scientific Reports. 2019;9(1):9772. doi:10.1038/s41598-019-46120-z.
A Randomized Placebo-Controlled Clinical Trial of Nicotinamide Riboside in Obese Men: Safety, Insulin-Sensitivity, and Lipid-Mobilizing Effects. Dollerup OL, Christensen B, Svart M, et al. The American Journal of Clinical Nutrition. 2018;108(2):343-353. doi:10.1093/ajcn/nqy132.
NR-SAFE: A Randomized, Double-Blind Safety Trial of High Dose Nicotinamide Riboside in Parkinson’s Disease. Berven H, Kverneng S, Sheard E, et al. Nature Communications. 2023;14(1):7793. doi:10.1038/s41467-023-43514-6.
Nicotinamide Riboside Is a Major NAD+ Precursor Vitamin in Cow Milk. Trammell SA, Yu L, Redpath P, Migaud ME, Brenner C. The Journal of Nutrition. 2016;146(5):957-63. doi:10.3945/jn.116.230078.
Implications of Altered NAD Metabolism in Metabolic Disorders. Okabe K, Yaku K, Tobe K, Nakagawa T. Journal of Biomedical Science. 2019;26(1):34. doi:10.1186/s12929-019-0527-8.
Nicotinamide Riboside and Nicotinamide Mononucleotide Facilitate NAD+ Synthesis via Enterohepatic Circulation. Yaku K, Palikhe S, Iqbal T, et al. Science Advances. 2025;11(12):eadr1538. doi:10.1126/sciadv.adr1538.
In Search of Molecular Correlates of Fibromyalgia: The Quest for Objective Diagnosis and Effective Treatments. Bonomi S, Oltra E, Alberio T. International Journal of Molecular Sciences. 2025;26(19):9762. doi:10.3390/ijms26199762.
Nuclear Sirtuins and Inflammatory Signaling Pathways. Mendes KL, Lelis DF, Santos SHS. Cytokine & Growth Factor Reviews. 2017;38:98-105. doi:10.1016/j.cytogfr.2017.11.001.
Regulation of SIRT1 and Its Roles in Inflammation. Yang Y, Liu Y, Wang Y, et al. Frontiers in Immunology. 2022;13:831168. doi:10.3389/fimmu.2022.831168.
SIRT1 Activators Suppress Inflammatory Responses Through Promotion of P65 Deacetylation and Inhibition of NF-κB Activity. Yang H, Zhang W, Pan H, et al. PloS One. 2012;7(9):e46364. doi:10.1371/journal.pone.0046364.
Nicotinamide Riboside-the Current State of Research and Therapeutic Uses. Mehmel M, Jovanović N, Spitz U. Nutrients. 2020;12(6):E1616. doi:10.3390/nu12061616.
SIRT1: A Likely Key for Future Therapeutic Strategies for Pain Management. Ilari S, Nucera S, Passacatini LC, et al. Pharmacological Research. 2025;213:107670. doi:10.1016/j.phrs.2025.107670.
Oxidative Stress, Inflammation, and Cellular Senescence in Neuropathic Pain: Mechanistic Crosstalk. Stojanovic B, Milivojcevic Bevc I, Dimitrijevic Stojanovic M, et al. Antioxidants (Basel, Switzerland). 2025;14(10):1166. doi:10.3390/antiox14101166.
Safety of Nicotinamide Riboside Chloride as a Novel Food Pursuant to Regulation (EU) 2015/2283 and Bioavailability of Nicotinamide From This Source, in the Context of Directive 2002/46/Ec. Turck D, Castenmiller J, de Henauw S, et al. EFSA Journal. European Food Safety Authority. 2019;17(8):e05775. doi:10.2903/j.efsa.2019.5775.
NRK1 Controls Nicotinamide Mononucleotide and Nicotinamide Riboside Metabolism in Mammalian Cells. Ratajczak J, Joffraud M, Trammell SA, et al. Nature Communications. 2016;7:13103. doi:10.1038/ncomms13103.
Nicotinamide Riboside, a Promising Vitamin B Derivative for Healthy Aging and Longevity: Current Research and Perspectives. Biţă A, Scorei IR, Ciocîlteu MV, et al. Molecules (Basel, Switzerland). 2023;28(16):6078. doi:10.3390/molecules28166078.
NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Yoshino J, Baur JA, Imai SI. Cell Metabolism. 2018;27(3):513-528. doi:10.1016/j.cmet.2017.11.002.
Dietary Interventions in the Management of Fibromyalgia: A Systematic Review and Best-Evidence Synthesis. Lowry E, Marley J, McVeigh JG, et al. Nutrients. 2020;12(9):E2664. doi:10.3390/nu12092664.
NAD+ Therapy in Age-Related Degenerative Disorders: A Benefit/Risk Analysis. Braidy N, Liu Y. Experimental Gerontology. 2020;132:110831. doi:10.1016/j.exger.2020.110831.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.